Management of Patient with Neuroleptic Malignant Syndrome
Keywords:
Neuroleptic Malignant Syndrome, Antipsychotic Drugs, NMS Treatment, Case Report, Dopaminergic MedicationsAbstract
Neuroleptic Malignant Syndrome (NMS) is a rare, life-threatening condition often induced by the use of antipsychotic drugs, characterized by hyperthermia, muscle rigidity, altered mental status, and autonomic dysfunction. This syndrome can be precipitated by antipsychotic medications, including haloperidol and fluphenazine, or by abrupt withdrawal of dopaminergic medications. This case report presents the management of a 56-year-old male patient admitted with decreased consciousness, muscle rigidity, and high fever, diagnosed with NMS. The patient was treated with supportive care, electrolyte correction, and medications including ceftriaxone, resfar, omeprazole, and others. The patient’s condition gradually improved with proper monitoring, and after intensive care, the patient was transferred to the ward. This report highlights the importance of early detection, discontinuation of causative drugs, and appropriate therapeutic interventions to reduce the mortality rate, which remains high at 20-30% if untreated. The treatment approach emphasizes symptom management, including fluid resuscitation and the use of medications like bromocriptine or dantrolene for severe cases.
Downloads
References
Paul T, Karam A, Paul T, Loh H, Ferrer GF. A Case Report on Neuroleptic Malignant Syndrome (NMS): How to Approach an Early Diagnosis. Cureus. 2022 Mar 31;14(3):e23695. doi: 10.7759/cureus.23695.
Marino, Paul. Marino’s The ICU Book. Fourth edition. Lippincott william & wilkins.2014.
Puspita, Okta, Bambang Hastha Yoga and Zullies Ikawati. “Antipsychotic-associated neuroleptic malignant syndrome (NMS) in schizophrenia patients: a narrative review.” IJPTher, Volume 5, Number 1, 2024: 65-75.
Guinart, Daniel, Fuminari Misawa, Jose M Rubio-Lorente, Justin Pereira, Renato de Filippis, Chiara Gastaldon, John M. Kane and Christoph U. Correll. “A systematic review and pooled, patient‐level analysis of predictors of mortality in neuroleptic malignant syndrome.” Acta Psychiatr Scand Suppl 144 (2021): 329 - 341.
Touzani,
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Riando Ginarsyah, Novita Anggraeni

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aCreative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.